-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib

Benzinga·02/03/2026 13:09:53
Listen to the news
  • This is the first trial combining Allarity's stenoparib with another anti-cancer agent



     
  • Stenoparib's favorable safety profile supports potential for use in combination regimens



     
  • Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US